Guests/Speakers
James Hiter (Host) is a lung cancer patient advocate, LCFA board member, and member of LCFA’s Speakers Bureau. He is living with KRAS G12D-driven lung cancer.
Stephanie Williams (Guest) is a Speakers Bureau member. Diagnosed with stage 2 non-small cell lung cancer (ALK+) at age 37, she now advocates for patients navigating treatment options and biomarker testing.
When “Sub-Q” Isn’t Just Medical Shorthand Anymore
For most people newly diagnosed with lung cancer, words like “IV,” “infusion chair,” and “port” become part of a whole new vocabulary almost overnight. But a growing number of patients are hearing a different term at their oncology appointments: subcutaneous, or SubQ. On this episode, host James Hiter sits down with fellow patient advocate Stephanie Williams to talk honestly about weighing subcutaneous cancer treatment vs IV delivery — not as an abstract medical comparison, but as something that changes what a treatment day actually looks like.
Stephanie brings a rare dual perspective to the conversation. Before she was ever a patient, she was a registered nurse who administered subcutaneous injections, such as insulin, blood thinners, and allergy shots, as part of her daily work. So when her care team raised the possibility of a subcutaneous option during her own treatment for ALK+ non-small cell lung cancer, it wasn’t an unfamiliar word. It was a technique she already trusted.
A Nurse’s Eye View, Then a Patient’s
Stephanie was diagnosed with stage 2 non-small cell lung cancer at 37, the mother of a kindergartner at the time. Surgery and chemotherapy came first. Later, biomarker testing revealed an ALK mutation, opening the door to targeted therapy. And eventually, to a conversation about how that therapy could be delivered.
“When you go subQ, you’re not going as deep into the body. It’s not as intrusive to your system, and it takes away a little bit of that risk,”
Drawing on the clinical knowledge she carried into the exam room as a patient. That’s not a small distinction for anyone who’s spent time tracking down a usable vein for an IV line, or weighing the small but real risks that come with repeated vascular access.
What Actually Changes With Subcutaneous Delivery
The appeal of subcutaneous delivery isn’t only clinical — it’s logistical. An IV infusion can take minutes to hours, depending on the drug and the setting. A subcutaneous injection, by contrast, is typically administered in under a minute, with a short observation period afterward for new medications.
“It’s less disruptive because it takes such a shorter amount of time than a traditional IV therapy would take. The prep doesn’t involve trying to find a suitable vein… and the recovery is just slapping on a wrap or a band-aid on that spot.” – Stephanie Williams, Patient Advocate
That time difference adds up. Fewer hours in an infusion chair means fewer hours away from work, family, and the ordinary routines that can start to feel impossible to protect during cancer treatment. James, who hosts the podcast while living with his own lung cancer diagnosis, put it simply: cancer takes a lot from patients, so any moment that can be reclaimed — even just the hour that used to go to an infusion — matters.
One question patients often ask is whether a faster, less invasive delivery method means giving something up in exchange — namely, effectiveness. Stephanie addresses this directly, noting that drugs formulated for subcutaneous administration are engineered specifically for that route into the body. The formulation changes; the outcome, according to available data, largely doesn’t.
Addressing the Practical Questions
Insurance coverage is often the first hurdle patients raise when a new delivery option comes up. Stephanie points to a few resources many patients overlook: insurance case managers, oncology nurse navigators, and — for many subcutaneous medications — direct support programs run by drug manufacturers. None of these resources help, though, if a patient doesn’t know a subcutaneous option exists for their treatment in the first place.
That’s the gap this episode is aimed at closing. Stephanie’s advice for anyone currently in treatment is straightforward: ask. “It’s always worthwhile to ask… If it is an option, it can have a great benefit for you. And thank goodness you asked the question,” she says. Patients don’t need clinical language to start the conversation — just the willingness to raise it: I heard subcutaneous delivery might be an option for some lung cancer medications. Is that something available to me?
A Conversation Between Peers
What sets this conversation apart is its format: two patients, talking as patients, about a topic that can otherwise feel entirely clinical. Stephanie’s nursing background gives her an unusually clear window into the mechanics of subcutaneous delivery, but it’s her experience as a patient — the missed veins, the infusion chairs, the calendar juggling — that makes the conversation land. For anyone currently weighing treatment delivery options, or simply hearing the word “subcutaneous” for the first time, this episode offers something clinical brochures often can’t: a fellow patient’s honest account of what changed, and why it mattered.
